| Name | Title | Contact Details |
|---|---|---|
Anthony Rossomando |
Chief Technology Officer | Profile |
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
MyDental360 - Know what matters. Find what works. Powered by Kulzer The information you want on the subjects that affect your everyday work. We cover them from every angle—in a concise view delivered right to your inbox. Your Benefits • Busine...
Ferring Pharmaceuticals, Inc. is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ABA Therapy for children with ASD, EBD, & developmental disabilities. We serve King County, WA including Kent, Renton, Seattle, Kirkland, Redmond, & more.